The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Leicester
About this trial
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition. This may lead to the development of new treatments aimed at lowering fat levels around the heart and in the rest of the body, specifically to treat HFpEF.
Eligibility criteria
Qualifiers
Participant is willing and able to give informed consent for participation in the study.
Aged ≥18 years old
Diagnosed with HFpEF by an experienced cardiologist or signs and symptoms of heart failure with a HFA-PEFF score ≥5
Able to understand written English
Disqualifiers
LV ejection fraction <45%
Recovered ejection fraction (previous ejection fraction <40%) unless reduced ejection fraction was in context of tachycardia induced cardiomyopathy (eg atrial fibrillation/atrial flutter)
Severe primary valvular heart disease
HFpEF due to infiltrative cardiomyopathy (cardiac amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy, restrictive cardiomyopathy/pericardial disease or congenital heart disease
Trial design
Treatments tested in this trial
- Not listed
Trial groups
130 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov